ICV will introduce U.S. and European Biotech and Medical Device companies to Investors, Potential Partners and Government Officials located in Beijing, Shanghai and Hong Kong.

 

ICV Delegation Visit Greater China 2017 will provide insights into operating throughout China and U.S. – China relations, as well as the opportunity to explore potential investment and cross-border partnering opportunities.

According to the World Health Organization, the population of individuals aged 60 or older is set to rise 90% in China to 240 million by 2020. Over this period, the healthcare sector in China will become a US$1 trillion a year business.

The Chinese market is developing rapidly, with technological breakthroughs that are driving innovation and an aggressive move towards cross-border collaboration, both for investments and licensing.

Ahead of the delegation visit, ICV will carefully curate one-on-one and group meetings based upon targeted objectives and designed to facilitate a variety of different partnering mechanisms for co-development and/or investment.

With a targeted approach and sustained investor engagement after the delegation visit, entry into Greater China can be transformational.

 
 

“China has so many white spaces where there is nothing that exists, and it’s very compelling. If you can bring it from the U.S., you can then avoid the fundamental scientific risk of developing something that’s completely unavailable.”

 – Judith Li, partner at the life science-focused Lilly Asia Ventures

 

 

Asia Placeholder
Asia

 

 

Resource Library: 2030 Agenda for Sustainable Development

 
Reports/Articles